4 years ago

Mogrify Closes Second Tranche of Series A, Raising $17 Million

  • Mogrify Limited, a Cambridge, England, UK-based biopharmaceutical company, has closed the second tranche of its Series A financing, raising $17 million and bringing the total raised in this round to $33 million

  • The funding will be used to advance Mogrify's immuno-oncology and ophthalmology programs, including iPSC-derived allogeneic cell therapies targeting hematological and solid malignancies, as well as in vivo reprogramming therapies aiming to address retinal degeneration, a leading cause of blindness, through to IND-enabling studies

  • The round was led by Parkwalk Advisors, with additional funding from strategic Corporate Pharma investor Astellas Venture Management, as well as 24Haymarket, co-Founder of Abcam PLC, Dr Jonathan Milner, and Mogrify CEO, Dr Darrin M Disley OBE.

      • ProblemHealthcare

      "There is a huge need for new treatments for diseases like cancer and blindness, and current treatments are often not effective enough."

      Solution

      "Mogrify is developing new cell therapies using its proprietary technology to reprogram cells to treat diseases like cancer and blindness. This is a more effective and efficient way to treat these diseases than current methods."

      Covered on